By the in silico prediction of potential HLA-A*02-presented peptides from RHAMM, the peptide R3 (ILSLELMKL) was first characterized as a highly immunogenic CD8+ T-cell epitope in AML patients [83]. Here, CD8A is linked to acute myeloid leukemia.